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Neutralizing TGF-b1 antibody infusion in neonatal rat delays
in vivo glomerular capillary formation1
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Neutralizing TGF-b1 antibody infusion in neonatal rat delays that are not organized into blood vessels appear in the
in vivo glomerular capillary formation. metanephric stroma. Vascular smooth muscle cell pre-
Background. The interruption of transforming growth cursors similarly migrate into the kidney as a componentfactor-b (TGF-b) signaling with dominant negative type II
of the vessel adjacent to the developing ureter and asTGF-b receptors in bovine glomerular endothelial cells abro-
individual cells not yet organized into blood vessels [2].gates capillary morphogenesis in vitro, and genetic defects in
the TGF-b1 signaling cascade in mice and humans result in Vascularization of developing glomeruli is first observed
abnormalities of blood vessel morphology. This study sought at the stage of comma- and S-shaped bodies, when endo-
to determine whether TGF-b1 participates in renal glomerular thelial cells and formed capillaries can be seen in thecapillary development in vivo.
cleft that invaginates the primitive epithelial vesicle [3].Methods. To inhibit TGF-b1 action, neutralizing anti–TGF-
Glomerular vascularization occurs through in situ vascu-b1 IgG was infused intra-arterially into the suprarenal aorta
of three-day-old rats, and the glomerular endothelial cell ap- logenesis, defined as the aggregation of angioblasts into
pearance was evaluated two days later by immunohistochemi- capillaries, and angiogenesis, which is the sprouting of
cal detection of the endothelium-specific von Willebrand fac- new capillaries from existing blood vessels.tor, in situ analysis of vascular endothelial growth factor
Some of the molecular mechanisms that lead to gen-receptor binding, and morphometric study of developing glo-
eral vascular and glomerular capillary development havemerular structures by transmission electron microscopy.
Results. The infusion of neutralizing the TGF-b1 antibody been elucidated [4, 5]. Homologous deletions of vascular
markedly reduced the invasion of comma- and S-shaped bodies endothelial growth factor (VEGF) receptors in mice,
by endothelial cells, and inhibited organization of endothelial lethal at embryonic day 8.5, show that VEGF receptor-2cells into capillaries in these structures. In addition, capillary
(VEGF-R2, KDR/Flk-1) is essential in endothelial celllumen formation and endothelial cell fenestration in devel-
lineage determination [6], whereas VEGF-R1 (flt-1) isoping cortical, but not in deep, already mature glomeruli were
inhibited by neutralizing TGF-b1 antibody. Seven days after necessary for the assembly of angioblasts into capillaries
TGF-b1 antibody infusion, glomeruli appeared normal, and [7]. In the developing mouse kidney, VEGF-R2 is highly
no reduction in glomerular number was observed. expressed in renal microvessels and angioblasts [1], and
Conclusions. These findings suggest that TGF-b1 plays a
VEGF, the ligand for VEGF-Rs, is similarly abundantcritical role in the formation of glomerular capillaries during
in renal epithelial cells during development [8]. The ad-renal development in the rat, and that flattening and fenestra-
ministration of neutralizing VEGF antibody in neonataltion of glomerular capillaries require the action of TGF-b1.
mice results in a profound reduction of glomerular vascu-
larization [9]. In mature animals, VEGF expression per-
sists in podocytes and other epithelial cells adjacent toRenal vascularization occurs as early as embryonic
fenestrated endothelium, suggesting that VEGF is neces-day 11 in the mouse, when a single blood vessel invades
sary for endothelial cell fenestration [8, 10, 11]. Indeed,the metanephros alongside the developing ureter [1].
the application of VEGF induces fenestrae in postcapil-At the same developmental stage, individual angioblasts
lary venules [12]. VEGF-producing tumors develop fen-
estrated endothelium in vivo [13], and in the context
1 See Editorial by Abrahamson, p. 1597 of basement membrane-derived matrix, VEGF induces
fenestrations in adrenal capillary endothelial cells in vitroKey words: rat kidney, glomerular endothelium, development, differ-
entiation, fenestrae. [14]. Hence, both glomerular vascularization and proba-
bly also fenestration require the action of VEGF.Received for publication December 30, 1998
Angiopoietin 1 and 2 exert their effects on endothe-and in revised form April 16, 1999
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10.5 gestation because of highly abnormal blood vessel leads to embryonic death at day 10.5 in 50% of homozy-
gous TGF-b1 and 100% of homozygous type II TGF-bformation [15], a defect also observed in mice with homol-
ogous deletions of angiopoietin 1 [16]. Angiopoietin 2 is receptor-deficient embryos. The survival of approxi-
mately half of homozygous TGF-b1 knockout embryosan inhibitory ligand for Tie2 [17], whose overexpression
in transgenic mice leads to the same phenotype as the has been ascribed to the effects of maternal TGF-b1
[32]. In mice deficient in TGF-b1 during embryogenesis,Tie2 deletion [18]. In humans with activating mutations
in Tie2, venous malformations characterized by an atten- the abnormalities in yolk sac blood vessel formation
ranged from a complete absence to a delayed formationuated smooth muscle layer are observed [19]. The dele-
tion of the receptor Tie1, which is structurally similar to of highly disorganized vessels, and in those capillaries
that did form, the normal association between the endo-Tie2 but does not interact with the angiopoietins, results
in embryonal death at day 14.5 of gestation, with abnor- thelium and yolk sac mesothelium was disrupted [32].
To date, no defect in vasculogenesis or renal vascularmalities suggesting a loss of endothelial integrity [15].
Like VEGF-R2 [1], Tie1 expression is observed in renal development has been reported in TGF-b3 knockout
mice [34, 35], and although renal developmental abnor-angioblasts in developing mouse kidney, cells that then
go on to vascularize glomeruli [20]. The endogenous malities have been described for the TGF-b2–deficient
mice, some of which developed dilation of renal tubulesligand for Tie1 and its precise role in glomerular vascu-
larization are not known. and the renal pelvis, defects in vascular morphogenesis
or vascularization of the kidneys was not described [36].Ephrins and their receptors, Ephs, are involved in
blood vessel pattern development [5]. They are thought The observation that mutations in endoglin, a TGF-
b1/TGF-b3 accessory receptor expressed only by endo-to guide homotypic interactions between endothelial
cells. In mouse embryos, for instance, an interaction be- thelial cells and necessary for TGF-b1 signaling [37], are
responsible for the autosomal-dominant disease heredi-tween ephrin B-2, which is expressed only by endothe-
lium of the arterial lineage, with counterreceptor Eph- tary hemorrhagic telangiectasia type 1 (HHT1, Osler-
Weber-Rendu disease) is also instructive [38]. BecauseB4 on endothelial cells of venous lineage, is necessary for
capillary network formation [21]. Eph-B1 is expressed in endoglin mutations have no apparent functional conse-
quence in nonendothelial cells but lead to severe, pro-human renal microvascular cells [22], and developing
and mature mouse glomeruli express Eph-B1 as well as gressive abnormalities in venule and capillary structure,
there must be a direct actions of TGF-b1 (or TGF-b3)its ligand ephrin B-1 [5]. This ephrin-Eph pair may direct
homotypic interactions between endothelial cells that on the development or maintenance of normal capillary
bed structure. However, because endoglin selectively ex-form the glomerular capillary network [5].
Transforming growth factor-b1 (TGF-b1) and its re- cludes TGF-b2 from interacting with most endothelial
cells [39], and TGF-b3–deficient mice have no evidentceptors also participate in the process of blood vessel
morphogenesis. abnormality in capillary morphogenesis, the phenotype
in patients with endoglin mutations probably resultsIn mice, a subcutaneous TGF-b1 injection rapidly
stimulates angiogenesis [23], and angiogenesis is aug- from defective TGF-b1 signaling. The lesion in HHT1
has been postulated to result from abnormal cell–cellmented in Chinese hamster ovary (CHO) cell tumors
stably transfected to produce excess TGF-b1, compared junction development and/or abnormal endothelial cell–
matrix interactions [38]. Mutations in another TGF-bwith similar tumors not producing TGF-b1 [24]. Because
TGF-b1 tends to inhibit endothelial cell proliferation in signaling receptor, ALK-1, similarly lead to the HHT
phenotype in humans [40] and strongly support a rolevitro [25], the angiogenic actions of TGF-b1 in vivo are
thought to be indirect and caused by, at least in part, for TGF-b in blood vessel morphogenesis.
This study sought to further define the role of TGF-TGF-b1–mediated production of angiogenic growth fac-
tors such as VEGF by nonendothelial cells [26, 27]. b1 in the process of renal glomerular capillary formation
in vivo. Because mice fully deficient in TGF-b1 or TGF-bHowever, TGF-b also directly regulates the process
of blood vessel formation. Capillary formation is stimu- type II receptors die prior to the onset of kidney develop-
ment, we chose to infuse neutralizing TGF-b1 antibodylated by TGF-b1 in three-dimensional cultures in the
absence of nonendothelial cells [28], and TGF-b1 coop- during a defined window of time in renal development
in vivo, leaving the synthesis of endogenous TGF-b1erates with basic fibroblast growth factor to stimulate
capillary formation and collagen gel invasion in vitro and its receptors intact. In rats, nephron development is
incomplete at birth and continues for the first 10 days[29, 30]. Similarly, bovine glomerular endothelial cells
in monolayer culture form capillaries in response to of neonatal life. In this study, nephron vascularization
was studied between days 3 and 5 after birth. AlthoughTGF-b1, an effect completely inhibited by dominant neg-
ative type II TGF-b receptors [31]. In mice made defi- neutralizing TGF-b1 antibody was not observed to alter
mature glomeruli or large blood vessels in the kidney,cient in TGF-b1 [32] or type II TGF-b receptors [33],
the capillary formation in the yolk sac is defective and it inhibited capillary lumen formation and glomerular
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capillary fenestration in immature glomeruli, and re-
duced endothelial cell invasion and capillary formation
in comma- and S-shaped bodies.
METHODS
Animal surgery
Pregnant female Sprague Dawley rats (Charles River
Laboratories, Wilmington, MA, USA) were handled by
the surgeon twice daily for at least three days prior to
parturition to accustom them to human contact. The
pups were similarly handled twice daily after birth until
the time of surgery. The lack of handling resulted in the
mother’s rejection of the pups after surgery. The rat pups
were left with their mother until the time of surgery, and
the mother had free access to food and water. Surgery
was performed on postnatal day 3. Pups were anesthe-
tized by inhalation with methoxyflurane. A transverse
abdominal incision was performed, and the suprarenal
and infrarenal aorta was exposed under a dissecting mi-
croscope. After the infrarenal aorta was clamped with
microvascular clip, a total of 8 mg of neutralizing chicken
anti–TGF-b1 IgG (Collaborative Biomedical Products,
Fig. 1. Schematic representation of the microinjection. After clampingBedford, MA, USA) in saline (2 mg/ml) was injected. of the infrarenal aorta, IgG was infused into the suprarenal aorta of
Purified chicken IgG (Sigma, St. Louis, MO, USA) simi- three-day-old neonatal rats, thus delivering the IgG into the renal circu-
lation.larly diluted in saline was injected into littermate controls.
Injections were performed using glass pipettes (0.2 to
0.3 mm at the tip) to puncture the aorta just above the
level of the renal arteries (Fig. 1), and a calibrated Hamil-
kidney was immersion fixed in 10% neutral-buffered for-ton syringe was used to control the volume of injectate.
malin solution for subsequent embedding in paraffin.Based on an average body weight of 3.5 to 4 g on postnatal
One fifth was placed in 4% formaldehyde/2% glutaralde-day 3, the plasma concentration of injected IgG was
hyde in 0.1 m phosphate buffer, pH 7.2 (4F-1G; Paragon,calculated to be approximately 12 to 16 mg/ml. In studies
Baltimore, MD, USA) for subsequent transmission elec-by the manufacturer, 1 mg of the anti–TGF-b1 IgG neu-
tron microscopy (TEM), and 2/5 of each were placedtralizes 0.72 ng active TGF-b1 in vitro. In rat plasma
into OCT and frozen over liquid nitrogen for VEGFcollected from conscious mature rats, latent TGF-b1 con-
binding studies. Serial cross sections (6 mm thick) werecentrations ranged from 5.3 to 12.2 ng/ml [41]. The active
processed for routine hematoxylin and eosin (H&E)TGF-b1 concentration was below an assay sensitivity of
staining and immunohistochemical analysis as described0.4 ng/ml. The dose of antibody used in this study is
later in this article.estimated to be capable of inhibiting 8.6 to 11.5 ng active
TGF-b1. This antibody fully inhibits capillary morpho- Immunohistochemistry
genesis by bovine glomerular endothelial cells in vitro
Immunohistochemical studies were performed as pre-at a concentration of 10 ng/ml [31]. Pressure was held
viously described [42]. The avidin-biotin immunoperoxi-over the injection site, and the aortic clamp was removed.
dase method was used to study the immunolocalizationAfter homeostasis was achieved, the abdomen was irri-
of von Willebrand factor (vWF) in neonatal rat kidneys.gated with saline and then closed in one layer with 7-0
Sections from control versus anti–TGF-b1 antibody-nylon. The pup was placed on sterile gauze under a heat
treated rat kidneys were placed on the same slide.lamp and was allowed to awaken. When fully awake, it
Briefly, the formalin-fixed paraffin sections were depar-was returned to its mother. The incision was checked
affinized with xylene followed by rehydration in a de-twice daily postoperatively. The 48-hour survival aver-
scending series of ethanols. Endogenous peroxidasesaged 76% and did not differ significantly between neu-
were quenched in 3% hydrogen peroxidase for 20 min-tralizing anti–TGF-b1 and control IgG-injected pups.
utes. The sections were treated with 0.4% pepsin (Sigma)
Histology in 0.01 N HCl for 30 minutes at 378C and rinsed in 0.5%
milk (Carnation nonfat dry milk) in Tris-buffered salineRat pups were again anesthetized, and both kidneys
were harvested without perfusion. Two fifths of each (TBS). Nonspecific binding sites were blocked by using
Liu et al: TGF-b1 and glomerular capillary formation 1337
1% normal goat serum (NGS) in 0.5% milk/TBS for 30 oxidase-conjugated antibody, respectively, as described
earlier in this article.minutes. The sections were then incubated overnight at
48C with a 1:1000 dilution of rabbit polyclonal anti-vWF
Vascular endothelial growth factor binding(Dako, Carpinteria, CA, USA). Subsequent procedures
Vascular endothelial growth factor binding sites inwere conducted at room temperature. The sections were
developing kidney were studied as previously describedrinsed in 0.5% milk/TBS followed by incubation with a
by Jakeman et al utilizing recombinant human [125I]1:200 dilution of biotinylated secondary goat anti-rabbit
VEGF165 ([125I]-rhVEGF165) [43]. Frozen tissue wasIgG (Vector, Burlingame, CA, USA) for 30 minutes.
sectioned at 8 mm thickness on a cryostat and thawBoth primary and secondary antibodies were diluted in
mounted onto Fisherbrand Superfrost/Plus microscopebuffer containing 1% NGS in 0.5% ml/TBS. The sections
slides (Fisher Scientific 12-550-15). The sections werewere rinsed again in 0.5% milk/TBS and then incubated
dried in a desiccator at 48C overnight and were then prein-with an avidin-biotin complex (ABC kit was from Vector
cubated for three hours in Dulbecco’s modified Eagle’sLaboratories) for 30 minutes. Slides were washed in wa-
medium (DMEM) supplemented with 10% fetal calf se-ter and developed in 3,39-diaminobenzidine (DAB) in
rum (FCS), 25 mm HEPES, 0.5 mm MgCl2, 4 mg/ml leu-TBS containing hydrogen peroxide (DAB kit was from
peptin, and 5 mm phenylmethylsulfonyl fluoride (PMSF)Vector Laboratories). After counterstaining with May-
at room temperature to remove endogenous ligand. Theer’s Modified Hematoxylin (Polyscientific, Bay Shore,
preincubation buffer was then removed, and the sectionsNY, USA), the sections were washed in water, dehy-
were covered by 50 ml of the same buffer containing 210drated in an ascending ethanol series followed by xylene,
pm [125I]-rhVEGF165 (0.5 mCi; Amersham Life Scienceand mounted with a cover slip using Permount (Fisher
Inc., Arlington Heights, IL, USA) in 2 ml buffer andScientific, Pittsburgh, PA, USA). As negative controls,
incubated for two hours. Nonspecific binding was deter-the primary antibody was omitted or substituted with
mined by including a 500-fold excess (120 nm) nonradio-nonimmune rabbit immunoglobulin (Dako #0903). No
active VEGF165 (R&D Systems Inc., Minneapolis, MN,staining occurred in control sections.
USA) in the binding buffer on adjacent sections. TheKidney sections from six separate pairs of postnatal
sections were rapidly washed in four one-minute changesday 5 littermates (anti–TGF-b1 and control IgG treated),
of ice-cold PBS containing 200 mm NaCl and 0.5 mmderived from six different mothers, were used for vWF
MgCl2, fixed for 10 minutes in 4% paraformaldehyde/immunohistochemical studies. Each slide was examined
2% glutaraldehyde in 0.1 m phosphate buffer (pH 7.2),for the presence, pattern of distribution, and intensity
rinsed for two to five seconds in distilled H2O, and driedof vWF staining. The intensity of staining in glomeruli
quickly at room temperature with a stream of air. The
at different stages of development was graded semiquan-
slides were dipped for two seconds into emulsion LM-1
titively as absent (0), intermediate (11), or strong (21). (Amersham Life Science Inc.), dried for one hour, and
All S-shaped bodies, cortical glomeruli, and deep glo- stored with desiccant at 48C for three weeks. They were
meruli in a given section were scored. Cortical glomeruli developed with Kodak D-19 and were counterstained
were defined as those lying within an approximate 150 with Vector hematoxylin.
mm band immediately below the zone of nephrogenesis. Kidney sections from six separate pairs of postnatal
Kidneys were also evaluated for localization of chicken day 5 littermates (injected with anti–TGF-b1 or control
anti–TGF-b1 and nonimmune IgG. Affinity-purified IgG), derived from six different mothers, were examined.
Texas-Red–conjugated donkey anti-chicken IgG (1:100; Each section was examined for the presence, pattern of
Accurate Chemical and Scientific Corp., Westbury, NY, distribution, and intensity of [125I]-rhVEGF165 binding.
USA) did not reveal any immunofluorescent staining in The intensity of labeling in glomeruli at different stages
frozen sections of kidneys from anti–TGF-b1 or chicken of development was graded semiquantitatively as absent
IgG-injected rats. Similarly, affinity-purified, biotin-con- (0), intermediate (11) or strong (21). All S-shaped bod-
jugated donkey anti-chicken IgG antibody (1:500; Jack- ies, cortical glomeruli, and deep glomeruli in a given
son Laboratories West Grove, PA, USA) developed with section were scored. Cortical glomeruli were defined as
DAB did not reveal staining for chicken IgG in frozen those lying within an approximate 150 mm band immedi-
sections or in paraffin-embedded fixed sections of kid- ately below the zone of nephrogenesis.
neys from anti–TGF-b1 or chicken IgG-injected rats.
Transmission electron microscopyKidneys were also evaluated for VEGF expression
using two purified polyclonal rabbit anti-VEGF antibod- One fifth of each kidney was fixed in 2% glutaralde-
ies (#PC315; Oncogene, Cambridge, MA, USA; and #sc- hyde and 4% formaldehyde in a 0.1 m phosphate buffered
507; Santa Cruz Biotechnology, Santa Cruz, CA, USA) saline, pH 7.2 (PBS; 4F-1G; Paragon, Baltimore, MD,
on frozen and paraffin-embedded sections. Detection USA), at 48C overnight, postfixed in 1% osmium tetrox-
ide in S Collidine buffer, enbloc stained with uranylwas by indirect immunofluorescence and was with a per-
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Fig. 2. Identification of cortical glomeruli in
toluidine blue-stained thick sections. (A) Post-
natal day 5, control IgG infused. (B) Postnatal
day 5, neutralizing anti-transforming growth
factor-b1 (TGF-b1) IgG infused. The boxes
indicate regions chosen for preparation of
transmission electron microscopy (TEM) thin
sections. The arrows point to cortical glomer-
uli. Cortical glomeruli were defined as those
lying within a region of not more than 150 mm
below the region of ongoing nephrogenesis.
The magnification was the same for A and B
(bar in B 5 100 mm).
acetate, dehydrated through a graded series of ethanols, cortical glomeruli chosen for one pair of samples is
shown in Figure 2. All glomeruli in a given section werepassed through propylene oxide then a 50/50 and 70/30
mixture of Polybed 812 and propylene oxide, and embed- then examined by transmission electron microscopy
(TEM) and photographed without selection by a techni-ded in Polybed 812. Embedded specimens were cured
for 24 hours at 608C and thick sectioned at 0.5 microns cian who was blinded to the experimental design.
Tissue from four separate pairs of littermates (TGF-on a porter blum MT-1 ultramicrotome. Thick sections
were stained with toluidine blue and examined under a b1 antibody and control IgG) was examined by TEM.
Three to five distinct sections were cut from each sample.light microscope for orientation. Thin sections were cut
at 0.1 mm, stained with lead citrate and uranyl acetate,
Morphometryand examined at 60 KV under a JEOL 1200EX or Philips
electron microscope. Comma-shaped bodies, S-shaped The SigmaScan program (The Computer Algebra
Center, Birmingham, UK) was used to evaluate TEMbodies, cortical glomeruli within a 150 mm band just
below the zone of nephrogenesis, as well as deep mature photographs. The total capillary loop area and the area
of open lumen were quantitated. Capillary lumen sizeglomeruli, were chosen for evaluation. An example of
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Fig. 3. von Willebrand factor (vWF) immunohistochemistry. The diaminobenzidine reaction product is brown. (A) Postnatal day 3. (B and D)
Postnatal day 5, control IgG infused. (C and E) Postnatal day 5, neutralizing anti-TGF-b1 IgG infused. (→) S-shaped bodies (magnification A, B,
and C, 340; D and E, 3160).
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was then expressed as the ratio of capillary lumen:capil- RESULTS
lary loop area. Glomerular basement membrane (GBM) von Willebrand factor expression
length, length of GBM with adjacent fenestrated endo- In three-day-old untreated rats, strong vWF immuno-
thelium, and length of GBM with adjacent foot processes reactivity was observed in large vessels and deep glomeruli,
were measured using the same program. The degree of and vWF immunoreactivity was also observed in cortical
endothelial cell fenestration and podocyte foot process glomeruli and S-shaped bodies (Fig. 3A). In five-day-
formation is expressed as the fraction of GBM with adja- old rats injected with control IgG, similarly strong vWF
cent fenestrated endothelium (or foot processes):total immunoreactivity was seen in large vessels and deep
GBM length. glomeruli, and vWF immunoreactivity was observed in
cortical glomeruli and S-shaped bodies (Fig. 3 B, D). In
Western blot analysis five-day-old rats injected with neutralizing TGF-b1 IgG,
Portions of kidneys from six rats (4 anti–TGF-b1, 2 vWF immunoreactivity in large vessels and deep glomer-
chicken IgG) that had been kept frozen at 2808C were uli did not differ from that observed in control littermates
sonicated in lysis buffer (50 mm Tris-HCl, pH 7.5, con- (Fig. 3C); however, vWF staining was weaker in cortical
taining 150 mm NaCl, 1% Triton X-100, 1 mm EDTA, glomeruli and S-shaped bodies (Fig. 3 C, E) when com-
pared with the control kidneys (Fig. 3 B, D). In kidneys1 mm EGTA, 10 mg/ml leupeptin, 10 mg/ml aprotinin,
from rats injected with neutralizing TGF-b1 antibody,10 mg/ml pepstatin, 1 mm pefanloc Sc, 1 mg/ml chymo-
several S-shaped bodies were devoid of vWF immunore-statin, and 1 mm benzamidine). Samples were then cen-
activity (Fig. 3E). The results of semiquantitative analysistrifuged at 14,000 3 g for 10 minutes at 48C, and the
of vWF immunoreactivity are shown in Table 1. Thesupernatants were collected. Sodium dodecyl sulfate-
number of rats and the total number of structures evalu-polyacrylamide gel electrophoresis (SDS-PAGE) was
ated as well as the average staining intensity are shown.performed under reducing conditions on a 12% poly-
On average, the vWF staining intensity (0, 11, and 21)acrylamide gel. The resolved proteins were transferred
was significantly less in cortical glomeruli and S-shapedto Immobilon-P membranes (Millipore, Bedford, MA,
bodies of kidneys from five-day-old rats injected withUSA). The blots were blocked for one hour with 5%
neutralizing TGF-b1 antibody two days earlier comparedmilk (Carnation nonfat dry milk) in TTBS (167 mm NaCl,
with that in kidneys from rats given control IgG.1% Tween-20, and 25 mm Tris, pH 6.8). The blots were
incubated overnight at 48C with purified rabbit poly-
[125I]VEGF binding in situ
clonal anti-VEGF IgG (4 mg/ml; Oncogene, Cambridge,
Vascular endothelial growth factor binding studiesMA) and one hour with horseradish peroxidase (HRP)-
were performed to assess the distribution of endothelialconjugated goat anti-rabbit IgG in 5% milk/TTBS. Detec-
cells in the developing kidneys. Strong [125I]VEGF label-tion was with the enhanced chemiluminescent method
ing of glomeruli and S-shaped bodies was observed in(ECL; Amersham).
kidneys from five-day-old rats injected with control IgG
two days earlier (Fig. 4 A, C). Labeling was almost com-Statistical analysis
pletely absent in serial sections incubated with a 500-
All values are expressed as the mean 6 sd. Differences fold excess unlabeled VEGF165 (Fig. 4 B, D). In rats
in vWF expression and VEGF binding between the three given neutralizing anti–TGF-b1 IgG, many S-shaped
groups (normal postnatal day 3, control IgG postnatal bodies were devoid of VEGF labeling (Fig. 4E), whereas
day 5, anti-TGF-b1 postnatal day 5) were evaluated by VEGF labeling was present in most glomeruli (not
analysis of variance (ANOVA) with posthoc Bonferroni/ shown). In kidney sections from rats treated with neu-
Dunn analysis. For TEM, the presence or absence of tralizing TGF-b1 IgG, [125I]VEGF binding also was fully
endothelial cells and/or capillaries in C- and S-shaped inhibited by unlabeled VEGF165 (Fig. 4F). Semiquanti-
bodies was compared by chi-square analysis; differences tative analysis of [125I]VEGF binding is shown in Table
in cortical glomerular capillary lumen size, endothelial 2. The number of rats and the total number of structures
fenestration, and food process formation between con- evaluated, as well as the average labeling intensity, are
trol IgG and TGF-b1 antibody groups were performed shown. On average, [125I]VEGF binding was much less
by unpaired t-test. The semiquantitative evaluation of in S-shaped bodies of kidneys from five-day-old rats in-
vWF staining and VEGF binding and the morphometry jected two days earlier with neutralizing TGF-b1 IgG
were done independently by two investigators, one of compared with labeling of S-shaped bodies in kidneys
whom was blind to the experimental groups. Quantita- from rats given control IgG. No difference in [125I]VEGF
tive data from the two investigators were essentially the labeling was observed in cortical and deep glomeruli
(Table 2).same for the same sections.
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Table 1. von Willebrand factor (vWF) expression
Postnatal day 5
Postnatal day 3
untreated Control IgG Anti-TGF-b1 IgG
(N 5 5) (N 5 6) (N 5 6)
C- and S-shaped bodies
Total number evaluated 181 359 345
vWF staining intensity 0.92 60.44 1.17 60.26 0.72 60.36a
Cortical glomeruli
Total number evaluated 222 399 355
vWF staining intensity 1.19 60.29 1.26 60.27 0.88 60.22a
Deep glomeruli
Total number evaluated 205 397 390
vWF staining intensity 1.74 60.06 1.16 60.33 1.4360.22
Data are mean 6 sd
a P , 0.05 compared to control IgG
Ultrastructure of comma- and S-shaped bodies lumen. Capillary loops of a cortical glomerulus from a
control IgG-injected rat on postnatal day 5 are shownComma-and S-shaped bodies were evaluated for the
in Figure 6B. In this example, three capillary loops con-presence and absence of endothelial cells and/or formed
taining flattened endothelium, which is fenestrated incapillaries within the capillary cleft. Formed capillaries
some areas, are observed. The capillary lumens are open,were defined as those structures within which red blood
and one of them contains an RBC. Podocyte foot pro-cells (RBCs) could be identified. Examples of S-shaped
cesses are well developed. Two examples of glomerularbodies from control IgG and neutralizing TGF-b1 IgG
capillary loops from two distinct rats infused with neu-injected rats are shown in Figure 5 A and B, respectively.
tralizing TGF-b1 IgG are shown in Figure 6 C and D.Table 3 shows the quantitative data. Of 17 comma- or
Two capillary loops are seen in Figure 6C and three inS-shaped bodies examined by TEM from four control
Figure 6D. The endothelial cells are very large. Theyrats, all but one contained identifiable endothelial cells,
are neither flattened nor do they appear fenestrated. Anand capillaries were observed in 14 of the 17 structures.
RBC is observed in two of the five loops, indicatingNo endothelial cells could be seen in the capillary clefts
that the capillary lumen is open; capillary lumen is notin nearly half of the 26 comma- and S-shaped bodies
observed in the remainder of the loops. The foot pro-evaluated in kidneys from four rats injected with neu-
cesses are well-developed in Figure 6D but not in Figuretralizing TGF-b1 IgG, and only 5 of the 26 structures
6C. Morphometric analysis is shown in Table 3. Thecontained formed capillaries. Hence, on average, there
mean loop area and the mean length of GBM/loop didwere significantly fewer endothelial cells in comma- and
not differ between the groups. However, the mean areaS-shaped bodies of kidneys from rats given neutralizing
of capillary loops occupied by open lumen (or RBCs)TGF-b1 IgG compared with rats injected with control
was markedly less in rats injected with neutralizing TGF-IgG. Moreover, the number of comma- and S-shaped
b1 IgG compared with control IgG-injected rats. Also,bodies containing identifiable capillaries was markedly
the mean length of GBM with adjacent fenestrated endo-lower in kidneys of rats given neutralizing TGF-b1 IgG
thelium was much lower in capillary loops from ratscompared with rats injected with control IgG.
injected with neutralizing TGF-b1 IgG compared with
Ultrastructure of cortical glomeruli rats given control IgG (Table 3). The mean length of
capillary loop GBM with adjacent foot processes tendedCortical glomeruli within a 150 mm band just below
to be slightly less in glomeruli of rats injected with neu-the zone of nephrogenesis were evaluated by TEM. Glo-
tralizing TGF-b1 antiserum compared with control IgGmeruli from four separate rats for each, neutralizing
injected rats, but this difference did not reach significance.TGF-b1, and control IgG injected rats were photo-
graphed by a technician blinded to the groups. In addi-
Ultrastructure of deep glomerulition, cortical glomeruli from two untreated rats on neo-
natal day 3 were examined. All cortical glomerular The ultrastructure of glomerular capillary loops from
rats at postnatal day 5 injected with control IgG or neu-capillary loops from control IgG and neutralizing TGF-
b1 IgG-injected rats present in the sections were sub- tralizing TGF-b1 IgG is shown in Figure 7. Five glomeruli
from 4 control pups and 11 glomeruli from 3 neutralizingjected to morphometry. An example of a capillary loop
in a cortical glomerulus at postnatal day 3 is shown in TGF-b1 IgG-injected pups were examined. In all deep
glomeruli examined, capillary lumens were open, andFigure 6A. The endothelium is not fenestrated, and the
endothelial cells appear very large and fill the capillary many contained RBCs. The endothelial cells appeared
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Fig. 4. In situ vascular endothelial growth factor (VEGF) binding studies. (A, C, and E ) [125I]VEGF165 binding in the absence of unlabeled
VEGF165. (B, D, and F ) Nonspecific [125I]VEGF165 binding in the presence of a 500-fold excess unlabeled VEGF165. (A–D) Postnatal day 5, control
IgG infused. (E and F) Postnatal day 5, neutralizing anti–TGF-b1 IgG infused. Arrows in C and E point to the vascular clefts of S-shaped bodies
(magnification A and B, 320; C–F, 380).
flattened and fenestrated, and the podocytes were well for total VEGF content using an immunopurified poly-
developed. No overt differences were observed in deep clonal anti-VEGF antibody that detects rodent VEGF
glomeruli of kidneys from rats given control IgG or neu- (Fig. 8). VEGF was present in all samples, and no obvi-
tralizing anti–TGF-b1 IgG. Morphometric analysis was ous differences in VEGF expression were discerned
not performed on deep glomeruli. when samples derived from controls were compared with
anti–TGF-b1 IgG-injected littermates. Indirect immuno-
Vascular endothelial growth factor expression fluorescence and immunohistochemistry were also per-
The frozen portions of kidneys from six rats, which formed on frozen and fixed, paraffin-embedded sections,
respectively, using two different antibodies. On postnatalwere derived from two different litters, were evaluated
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Table 2. In situ vascular endothelial growth factor (VEGF) binding
Postnatal day 5
Postnatal day 3
untreated Control IgG Anti-TGF-b1 IgG
(N 5 3) (N 5 6) (N 5 6)
C- and S-shaped bodies
Total number evaluated 101 171 133
VEGF binding intensity 1.39 60.19 1.52 60.11 0.88 60.38a
Cortical glomeruli
Total number evaluated 132 165 148
VEGF binding intensity 1.70 60.12 1.60 60.19 1.4260.33
Deep glomeruli
Total number evaluated 132 232 226
VEGF binding intensity 1.90 60.02 1.96 60.02 1.9560.08
Data are mean 6 sd.
a P , 0.01 compared to control IgG
Fig. 5. Transmission electron micrograph of comma-shaped bodies. (A) Postnatal day 5, control IgG infused. (B) Postnatal day 5, neutralizing
anti–TGF-b1 IgG infused. Abbreviations are: VE, cells destined to become visceral epithelial cells; PE, cells destined to become parietal epithelial
cells; R, red blood cell; and TL, tubule lumen. Arrows point to vascular clefts. (A) Endothelial cells are invading the cleft; the RBC indicates a
patent capillary. (B) No cells are observed within the vascular cleft (magnification for A and B is the same; the bar 5 2 mm).
day 1, VEGF immunoreactivity was detected in podo- renal aorta of three-day-old rats, and the glomerular
cytes of immature glomeruli and in S-shaped bodies (data endothelial cell appearance was evaluated two days later.
not shown). VEGF protein expression was below the Based on immunohistochemical detection of the endothe-
lium-specific vWF, in situ detection of VEGF receptors,level of sensitivity for these antibodies in rat kidneys on
also relatively endothelial cell specific, and morphomet-postnatal days 3 and 5.
ric analysis of developing glomerular structures by TEM,
the work shows that neutralizing TGF-b1 antibody re-
DISCUSSION duces invasion of comma- and S-shaped bodies by endo-
This work was prompted by our previous observation thelial cells and inhibits capillary lumen formation and
that the interruption of TGF-b signaling with dominant endothelial cell fenestration in developing cortical, but
negative type II TGF-b receptors in bovine glomerular not in deep, mature glomeruli. We conclude that TGF-1
endothelial cells abrogates capillary morphogenesis in plays an important role in the formation of glomerular
vitro [31]. We now sought to determine whether TGF- capillaries during renal development in the rat.
b1 also participates in glomerular capillary development Reduced vWF immunoreactivity two days after the
in vivo. To inhibit TGF-b1 action, neutralizing anti– injection of the neutralizing TGF-b1 IgG was the first
piece of evidence suggesting that TGF-b1 affects endo-TGF-b1 IgG was infused intra-arterially into the supra-
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Table 3. TEM morphometry (postnatal day 5)
Control IgG Anti-TGF-b1 IgG
(N 5 4) (N 5 4) P value
Comma-shaped bodies
Total number evaluated 9 12
Number containing endothelial cells 8 5 0.003
Number containing patent capillaries 6 0 0.001
S-shaped bodies
Total number evaluated 8 14
Number containing endothelial cells 8 8 0.03
Number containing patent capillaries 8 5 0.003
Cortical glomeruli
Total number evaluated 39 47
Total number of capillary loops 118 140
Mean loop area lm2 45.1169.41 49.34 68.53 0.56
Mean open lumen area lm2 13.3462.42 6.41 62.37 0.02
Ratio loop:lumen area 0.32 60.04 0.12 60.05 0.02
GBM mean length/loop lm 26.0765.63 28.31 65.13 0.25
GBM with adjacent fenestrated endothelium lm 7.7062.11 2.22 61.54 0.02
Fraction of GBM with adjacent fenestrated endothelium 0.30 60.08 0.09 60.04 0.02
GBM with adjacent foot processes 17.21 64.30 12.87 61.29 0.25
Fraction of GBM with adjacent foot processes 0.58 60.13 0.44 60.14 0.15
thelial cell phenotype in the developing rat kidney. This hibited by 500-fold excess unlabeled VEGF165 (Fig. 4).
In response to the neutralizing TGF-b1 IgG injection,finding could be due to a reduction of endothelial cells
within immature glomerular structures, delayed matura- there was a striking reduction in [125I]rhVEGF165 label-
ing of capillary clefts in comma- and S-shaped bodiestion of endothelial cells, or a specific effect of TGF-b1
on vWF expression. We are not aware of any reports (Table 2). Not shown in the Table 2, [125I]rhVEGF165
binding was completely absent from 30 6 13% of comma-suggesting a role of TGF-b1 in regulating vWF expres-
sion, synthesis, packaging, or release. Also, the findings and S-shaped bodies of rats given neutralizing TGF-b1
IgG compared with only 7 6 5% in rats injected withthat the neutralizing IgG in this study altered vWF immu-
noreactivity only in immature nephron structures and control IgG. This marked reduction in binding is in good
agreement with our observation that endothelial cellscortical glomeruli, but not in deep glomeruli or large
vessels, suggest that a direct effect of reduced TGF-b1 were absent from approximately 50% of C- and S-shaped
bodies examined by TEM compared with the absenceaction on vWF is not likely. On neonatal day 10, vWF
immunoreactivity in kidneys from rats given neutralizing of endothelial cells from only 6% of these structures in
rats given the control IgG. By contrast to the findingsTGF-b1 or control IgG seven days earlier did not differ
nor did the number of glomeruli (data not shown). It for binding in the nephrogenic zone of the developing
kidneys (Fig. 4E), no discernible difference of [125I]rh-was therefore concluded that any effect of the neutraliz-
ing TGF-b1 IgG on glomerular capillary formation had VEGF165 binding was observed in cortical or deep glo-
meruli (data not shown). These findings are consistentdissipated by neonatal day 10.
Because even extremely immature endothelial cells, with the notion that endothelial cells are absent from a
significant fraction of comma- and S-shaped bodies inincluding renal angioblasts, express VEGFR2 (flk-1), we
reasoned that examination of VEGF receptor expression rats given neutralizing TGF-b1 IgG but that an absence
of endothelial cells could not explain the reduction inin the developing kidney might help determine whether
the loss of vWF immunoreactivity in less mature glomer- vWF immunoreactivity in cortical glomeruli of rats given
neutralizing TGF-b1 IgG.uli is due to inhibition of endothelial cell migration into
these structures as opposed to delaying endothelial cell To clearly define the nature of the changes in endothe-
lial cells after TGF-b1 IgG administration, TEM and mor-maturation. Since TGF-b1 inhibits VEGFR2 receptor
expression by endothelial cells [44], any reduction in TGF- phometry were performed. Of 17 comma- and S-shaped
bodies examined in control rats, all but one containedb1 activity produced by neutralizing TGF-b1 IgG should
not result in a loss of VEGF receptor expression. In our endothelial cells within the capillary cleft, and all but
three showed evidence of patent capillaries. By contrast,hands, in neonatal rat kidney, specific VEGFR2 antibod-
ies were only weakly reactive and not informative (data of 26 comma- and S-shaped bodies evaluated in rats
given the neutralizing TGF-b1 IgG, endothelial cellsnot shown). However, a strong and specific signal was
obtained when in situ VEGF165 binding studies were were identified in only 13 (50%), and patent capillaries
in only five of these structures (Fig. 9). These findingsperformed; [125I]rhVEGF165 binding was completely in-
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Fig. 6. Transmission electron micrograph of cortical glomeruli. (A) Postnatal day 3. (B) Postnatal day 5, control IgG infused. (C and D) Postnatal
day 5, neutralizing anti–TGF-b1 IgG infused. Abbreviations are: En, endothelial cell; CL, capillary lumen; R, red blood cell. (B) Capillary lumens
are open, and fenestrated endothelium is present. (C and D) RBCs are observed in two loops; the remainder of the loops are filled with
nonfenestrated endothelium (bars 5 2 mm).
strongly suggest that the neutralizing TGF-b1 IgG inter- In cortical glomeruli of rats given the neutralizing
TGF-b1 IgG, endothelial cells were found to line allferes with the invasion of capillary clefts in comma- and
S-shaped bodies by endothelial cells. Furthermore, in capillary loops, but these cells differed markedly in struc-
ture when compared with endothelial cells in controlthe control rats, capillaries were identified in six of the
eight comma-shaped bodies containing endothelial cells, rats. Morphometric analysis revealed that the size of the
capillary loops did not differ, nor was the total length ofwhereas in neutralizing TGF-b1 IgG-treated rats, no cap-
illaries were observed in the five comma-shaped bodies GBM altered by the neutralizing TGF-b1 IgG. However,
the endothelial cells in capillary loops of rats injectedthat contained endothelial cells (Table 3). These obser-
vations suggest that neutralizing TGF-b1 IgG may also with neutralizing TGF-b1 IgG appeared much larger
than those lining control glomerular capillaries, and theinterfere with the assembly of endothelial cells into capil-
laries. A direct role for TGF-b1 in the process of endo- mean cross-sectional area of open lumen was markedly
reduced (Table 3). Furthermore, although approximatelythelial cell assembly into capillaries has been described
in vitro for endothelial cells derived from bovine brain 30% of the GBM in cortical glomerular capillary loops
contained adjacent fenestrated endothelium in control[45] and glomerular capillaries [31].
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Fig. 7. Transmission electron micrograph of deep glomeruli. (A) Postnatal day 5, control IgG infused. (B) Postnatal day 5, neutralizing anti–TGF-
b1 IgG infused. Abbreviations are: En, endothelial cell; CL, capillary lumen; R, red blood cell. Open capillary lumens and fenestrated endothelium
are seen in both examples. Magnification for A and B is the same (bar 5 2 mm).
and Tomita to localize strongly to renal glomeruli [9]. By
contrast, we found no evidence of anti–TGF-b1 antibody
localization to glomeruli in our study. The failure to find
anti–TGF-b1 antibodies may relate to the low dose of
antibody employed, and suggests that antibody-mediated
endothelial cell injury does not account for the changes
in endothelial cell morphology observed in this study.
Although our study provides strong evidence that
TGF-b1 is necessary for glomerular vascularization in
vivo, the mechanisms whereby TGF-b1 acts on endothe-
lial cells remain unclear. It is possible that the actions
Fig. 8. Vascular endothelial growth factor (VEGF) immunoblot. of TGF-b1 are, in part, indirect. VEGF expression is
Treatment with anti–TGF-b1 IgG or control IgG is indicated at the
known to be stimulated by TGF-b1 [27, 46]. Becausetop. Each lane is marked by sample number. Samples 11-2, 11-4, and
11-11 are from littermates, as are samples 13-2, 13-6, and 13-8. VEGF appears to play a critical role in the process of
endothelial cell fenestrae formation [12, 14], it is possible
that our findings in cortical glomeruli relate to the inhibi-
tion of VEGF synthesis. Similarly, reduced comma- and
rats, only 9% of GBM had adjacent fenestrated endothe- S-shaped body invasion by endothelial cells and reduced
lium in rats given neutralizing TGF-b1 IgG. The findings capillary formation in these structures could relate to
in cortical glomeruli are interpreted to indicate that reduced VEGF synthesis. However, by Western blot
TGF-b1 is necessary for endothelial cell flattening and analysis, we found no change in renal VEGF protein
fenestration in developing glomeruli. The alternative content after anti–TGF-b1 antibody administration (Fig.
possibility, namely that inhibition of TGF-b1 activates 8), a finding that does not support the notion that anti–
endothelial cells, causing them to loose fenestrae, once TGF-b1 IgG inhibited VEGF synthesis. Also of note, if
formed, is unlikely, as the neutralizing TGF-b1 IgG had maintenance of glomerular endothelial cell fenestrae is
no effect on endothelium of deep, more mature glomer- indeed dependent on ongoing VEGF synthesis by podo-
uli in these neonatal rats (Fig. 7). cytes, as previously suggested by Simon et al [11], one
Kitamoto, Tokunaga, and Tomita performed similar might have expected loss of fenestrae in deep glomeruli,
studies to those reported in our study using neutralizing if VEGF synthesis was inhibited, which was not ob-
VEGF antibody [9]. In their studies, a much higher dose served. However, because immunostaining of tissues
of antibody than that in this study was employed. Anti- with anti-VEGF antibodies was unrevealing beyond
postnatal day 3, the possibility still exists that inhibitionVEGF antibodies were found by Kitamoto, Tokunaga,
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Fig. 9. Summary of the morphometric data.
(A) Absence or presence of endothelial cells
in capillary clefts of C- and S-shaped bodies.
(B) Absence or presence of capillaries in capil-
lary clefts of C- and S-shaped bodies. (C) Size
of cortical glomerular capillary loops. (D) En-
dothelial cell morphometry in cortical glomer-
uli (hatched bars, control; solid bars, anti–
TGF-b1 Ab; *P 5 0.02.)
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